Fluorocyclopentenylcytosine methods of use
The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
1. A method of treating a tumor comprising administering to a human subject in need thereof an oral dosage form comprising an effective amount of a compound of formula (I)
or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, at a dosage of about 300-1,000 mg/day, wherein the tumor is pancreatic or bladder cancer.
2. The method of claim 1 , wherein the dosage is about 500-700 mg/day.
3. The method of claim 1 , wherein the dosage is about 6-12 mg/kg/day.
4. The method of claim 1 , wherein the oral dosage form is administered 5 to 7 days per week.
5. The method of claim 1 , wherein the oral dosage form is administered 5 to 7 days per week for 3 consecutive weeks followed by 1 off-week during which the oral dosage form is not administered, or for 4 consecutive weeks.
6. The method of claim 5 , wherein a dosing cycle consists of either 3 consecutive weeks of treatment followed by 1 off-week, or 4 consecutive weeks of treatment, and the oral dosage form is administered for up to 12 dosing cycles.
7. The method of claim 1 , wherein the oral dosage form provides a C max of about 700-1,100 ng/mL after a single administration.
8. The method of claim 1 , wherein the oral dosage form provides an AUC 0-t (0-24 hours) of about 8,000-10,000 hr·ng/mL after a single administration.
9. The method of claim 1 , further comprising administering radiation or an anti-tumor agent to the subject.
10. The method of claim 1 , further comprising administering an anti-tumor agent selected from the group consisting of antimetabolites, DNA-fragmenting agents, DNA-crosslinking agents, intercalating agents, protein synthesis inhibitors, topoisomerase I poisons, topoisomerase II poisons, microtubule-directed agents, kinase inhibitors, polyphenols, hormones, hormone antagonists, death receptor agonists, immune checkpoint inhibitors, anti-programmed cell death 1 (PD-1) receptor antibodies and anti-programmed cell death ligand 1 (PD-L1) antibodies.
11. The method of claim 1 , further comprising administering an anti-PD-L1 antibody to the subject.
12. The method of claim 1 , further comprising administering an anti-PD-1 antibody to the subject.
13. The method of claim 1 , wherein the oral dosage form is a solid.
14. The method of claim 1 , wherein the oral dosage form is a tablet.
15. The method of claim 1 , wherein the oral dosage form is a capsule.
16. The method of claim 9 , wherein the anti-tumor agent is a DNA-crosslinking agent selected from a group consisting of chlorambucil, cisplatin, cyclophosphamide and nitrogen mustard and derivatives thereof.
17. The method of claim 16 , wherein the DNA-crosslinking agent is cisplatin.
18. The method of claim 9 , wherein the anti-tumor agent is a microtubule-directed agent selected from a group consisting of colcemid, colchicine, paclitaxel, vinblastine and vincristine derivatives thereof.
19. The method of claim 18 , wherein the microtubule-directed agent is paclitaxel.
20. The method of claim 1 , wherein the dosage is about 400-1,000 mg/day.
21. The method of claim 20 , wherein the dosage is about 400-800 mg/day.